KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022 : vimarsana.com

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today

Related Keywords

Phoenix , Arizona , United States , American , Edwardj Duckworth , Ben Palleiko , Exchange Commission , Kalvista Pharmaceuticals Inc , Nasdaq , American Academy Of Allergy , Kalvista Pharmaceuticals , American Academy , Asthma Immunology , Annual Scientific Meeting , Associated With Early Symptom Relief , Patients With Hereditary Angioedema , Senior Scientist Biochemistry , Patient Global Impression , Change With Attack Resolution , Rescue Medication , Paul Audhya , Vista Pharmaceuticals , Looking Statements , Securities Litigation Reform Act , Kalvista , Harmaceuticals , Resent , Ata , Ral , Emand , Herapy , Kvd900 , Faaaai , 022 ,